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Abstract 
Children with autism spectrum disorders (ASD) often suffer gastrointestinal problems 
consistent with imbalances in the gut microbial population. Treatment with antibiotics or 
pro/prebiotics has been postulated to regulate microbiota and improve gut symptoms, but 
there is a lack of evidence for such approaches, especially for prebiotics. This study 
assessed the influence of a prebiotic galactooligosaccharide (B-GOS) on gut microbial 
ecology and metabolic function using faecal samples from autistic and non-autistic 
children in an in vitro gut model system. Bacteriology was analysed using flow cytometry 
combined with fluorescence in situ hybridization and metabolic activity by HPLC and 
1
H-NMR. Consistent with previous studies, the microbiota of ASD children contained a 
higher number of Clostridium spp. and a lower number of bifidobacteria compared to 
non-autistic children. B-GOS administration significantly increased bifidobacterial 
populations in each compartment of the models, both with autistic and non-autistic 
derived samples, and lactobacilli in the final vessel of non-autistic models. In addition, 
changes in other bacterial population have been seen in particular for Clostridium, 
Rosburia, Bacteroides, Atopobium, F. prausnitzii, Sutterella spp. and Veillonellaceae. 
Furthermore, the addition of B-GOS to the models significantly altered short chain fatty 
acid production in both groups, and increased ethanol and lactate in autistic children.  
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Autism typically develops in childhood, and it is considered as “a systemic 
spectrum disorder with multiple development trajectories with an incidence four times 
higher in males than in females” (Grossi 2014). In addition to behavioural traits, GI 
abnormalities such as diarrhoea, constipation, bloating, and abdominal pain are common 
in autism and they seem to contribute to, and exacerbate, overall behaviour of children 
(irritability, sleeplessness, posturing) (Van De Sande 2014). A cross talk exists between 
the gut microbiota and central nervous system (CNS) mediated via a range of different 
chemical, immunological and signalling interactions that form part of the gut-brain axis. 
Several studies have demonstrated the role of the gut microbiota in neurodevelopment 
and mental health (Foster 2013) and there is increasing evidence associating gut 
microbial dysbiosis with GI problems that might affect autistic children.  
Bacteria such as Clostridium spp., Desulfovibrio spp. and Streptococcus spp. are 
dominant in the guts of ASD children. Finegold et al. found nine unique species of 
clostridia in autistic children compared to controls (Finegold 2002). Song et al., using 
qPCR analysis, found higher levels of C. boltea and Clostridium cluster I and XI (Song 
2004). Furthermore, Parracho and co-authors, using FISH analysis, found greater number 
of species derived from the C. histolyticum group (Clostridium clusters I and II) 
(Parracho 2005). Desulfovibrio group was found to be ten times higher in the gut 
microbiota of autistic children compared to controls (Finegold 2010; Finegold 2011).  
High-throughput sequencing has been used in more recent studies to determine 
bacterial composition of faecal samples from autistic children. The genera Prevotella, 
Coprococcus, and unclassified Veillonellaceae have been found in lower abundance in 
autistic individuals (Kang 2013) with high genus Sutterella spp. (Wang 2013; William 
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2012). In addition, Bifidobacterium species decreased in ASD, comparing to the non-
autistic control (De Angelis 2013).  
 Metabolic associations have also been identified with ASD and may be attributed 
to gut dysbiosis in autistic individuals. Abnormalities have been reported in tryptophan 
metabolism where higher amount of indole derivates in the blood and higher levels of 
IAG (indolyl-acryuloyl-glycine) in the urine of autistic children have been identified. 
Increased abundance of Clostridium spp. in the ASD-associated microbiota may 
contribute to these metabolic alterations as these organisms can metabolise tryptophan 
(Bingham 2003). Metabonomic studies also identified alterations in nicotinic acid 
metabolism (Yap 2010) and amino acid deficiencies in autism with restricted diets, 
modified gut microbial population and GI symptoms being suggested as potential 
contributors (Ming 2012).  
Modulation of gut microbiota is an interesting potential strategy to reduce 
presence of harmful microorganisms and their metabolites that might be involved in 
negative stimulation of CNS and affect behaviour (Shaw 1995; Sandler 2000 ). Treating 
GI disorders in ASD with antibiotics or pro/prebiotics has been postulated to regulate 
microbiota and improve gut symptoms, but the evidence is scarce, especially for 
prebiotics.  
The bifidogenic properties of B-GOS (Bimuno®, Clasado Biosciences Ltd., 
Buckinghamshire, UK) have been investigated in vitro and in human intervention studies 
involving healthy volunteers, and conditions that have a purported microbial input such 
as IBS, travellers’ diarrhoea and obesity (Tzortzis 2005;  Depeint 2008;  Vulevic 2008; 
Silk 2009;  Drakoularakou 2009;  Vulevic 2013). Recently, B-GOS was also shown to 
 by guest on N
ovem
ber 24, 2016
http://fem
sec.oxfordjournals.org/
D
ow
nloaded from
 
 5 
reduce cortisol secretion and anxiety in healthy volunteers (Schmidt 2015). Cortisol is a 
reliable marker of stress and hypothalamic pituitary adrenal (HPA) axis activity. B-GOS 
supplementation lowered cortisol reactivity and modulated attention to emotional stimuli 
compared to a placebo group, supporting the hypothesis that gut microbiota might have a 
role in behavioural traits (Schmidt 2015). 
Our study aimed to assess the effects of B-GOS (65% GOS content) on gut 
microbial ecology and metabolic end products of microbial fermentation. We used in 
vitro, three-stage, continuous gut model systems, inoculated with faecal samples of 
autistic and non-autistic children, that simulated different physicochemical characteristics 
of the proximal, transverse and distal colons.  
 
Materials and methods 
Substrate 
The B-GOS product was supplied by Clasado Biosciences Ltd. The mixture was in syrup 
format consisting of 65% (w/v) GOS, 10.1% (w/v) lactose, 22% (w/v) glucose, 1.8% 
(w/v) galactose.  
Faecal inoculation 
Faecal samples were obtained from three non-autistic children and three autistic child 
donors (male, aged 5-10 years-old) who were free of any metabolic and gastrointestinal 
diseases, were not taking probiotic or prebiotic supplements, and had not taken antibiotics 
6 months before faecal sample donation. Autistic children had formal diagnosis of mild 
autism. None of the children followed any specific or restricted diet. 
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All parents then provided written informed consent for use of their children’s faeces in 
the study. This study was approved by The University of Reading research Ethics 
Committee (UREC 15/20). Faecal samples were placed in an anaerobic jar 
(AnaeroJarTM 2.5 L, Oxoid Ltd) including a gas-generating kit (AnaeroGenTM, Oxoid). 
An aliquot of 20 g of samples were diluted in 100 ml anaerobic PBS (0.1 mol/L 
phosphate buffer solution, pH 7.4, w/w) and homogenised (Stomacher 400, Seward, West 
Sussex, UK) for 2 minutes at 240 paddle beats per minute. Samples were added to 
anaerobic fermenters within 15 minutes of voiding. 
Three stage continuous culture gut model system 
Physicochemical conditions in the colon were replicated in a continuous culture system, 
comprised of a cascade of three glass fermenters of increasing working volume connected 
in series. A small scale version of the validated system described by Macfarlane et al. 
(1998) was used in this study, with vessels (V) representing the proximal (V1, 80ml, 
pH=5.5), transverse (V2, 100ml, pH=6.2), and distal colon (V3, 120ml, pH=6.8). The 
systems were inoculated with 20% (wt:v) faecal homogenate from either non-autistic and 
autistic children volunteers in a growth medium (Macfarlane 1998). Following 
inoculation, the colonic model was run as a batch culture for 24 h in order to stabilise 
bacterial populations prior to the initiation of medium flow. After 24 h (T0), the medium 
flow was initiated and the system ran for at least 8 full volume turnovers to allow for 
steady state to be achieved (SS1). SCFA profiles (+/-5%) were assessed before starting 
B-GOS administration. Taking into account the operating volume (300 mL) and the 
retention time (48 h, flow rate 6.25 mL/h) of the colonic model system, a syrup 
containing GOS (2g/daily, equivalent to 1g of GOS) was added daily into V1. The syrup 
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was added to the system for at least a further 8 volume turnovers upon which steady state 
2 (SS2) was achieved. Aliquots of 4.5 mL were removed at SS1 and SS2. 
Short chain fatty acids (SCFAs) analysis by HPLC 
The production of SCFAs in the fermentations was determined by HPLC (Merck, NJ) as 
previously described by Rodriguez-Colina et al. 2013. Twenty µL of each sample was 
injected with a run time of 45 min. Peaks were integrated using Atlas Lab managing 
software (Thermo Lab Systems, Mainz, Germany). Quantification of the samples was 
obtained through calibration curves of lactic, acetic, propionic, butyric and formic acids 
in concentrations 12.5, 25, 50, 75 and 100 mM. 
In vitro enumeration of bacterial population by FISH-FCM 
Bacterial composition in the gut models was analysed for using fluorescence in situ 
hybridization combined with flow cytometry (FISH-FCM). 750 µl of samples were 
centrifuged at 1136 x g for 5 min. Pellets were re-suspended in 375 µL of filtered PBS 
(using a 0.22 µm PVDF membrane) and fixed in 1125 µL of 4% (v/v) paraformaldehyde. 
After 4 hours incubation at 4 °C, samples were washed twice using 1 mL of PBS, re-
suspended in 600 µL PBS-ethanol (1:1, v/v) and stored at -20 °C. Permeabilisation steps 
were performed using 30 µL of the fixed samples added to 500 µL PBS and centrifuged 
at 1136 x g for 3 min. Pellets were re-suspended using 100 µL of filtered TE-FISH 
(Tris/HCl 1 M pH 8, EDTA 0.5 M pH 8, distilled H2O, 0.22 µm PVDF membrane) 
containing lysozyme (1 mg/mL of 50,000 U/mg protein) and incubated for 10 min at 
room temperature. Solutions containing the samples were then vortexed and centrifuged 
at 1136 x g for 3 min. Pellets were washed with 500 µL PBS and centrifuged (1136 x g, 3 
min). Hybridisations were performed by re-suspending the pellets in 150 µL of 
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hybridisation buffer (5M NaCl, 1M Tris/HCl pH8, 30% formamide, ddH2O, 10% SDS), 
vortexed and centrifuged (1136 x g, 3 min). Pellets were then re-suspended in 1 mL of 
hybridisation buffer and 50 µL aliquoted into Eppendorf tubes. The probes used (Sigma 
Aldrich Ltd., Poole, Dorset, UK) are reported in Table 1 (Wallner 1993;  Daims 1999;  
Langendijk 1995;  Harmsen 1999;  Manz 1996;  Franks 1998;  Walker 2005;  Harmsen 
2000;  Hold 2003;  Devereux 1992;  Poulsen 1995;  Harmsen 2002;  Lay 2005). NON 
EUB338 and EUB338 I-II-III linked at their 5’ end either to Alexa488 and Alexa647. 
Group specific probes were linked with Alexa647 at their 5’ end. 4µL of each probe and 
4 µL of Eub338 I-II-III (linked to Alexa488) were added to the working solution and 
incubated overnight at 35°C in a heating block. After 12 hours incubation, an aliquot of 
150 µL hybridisation buffer was added to the working solution, vortexed and centrifuged 
(1136 x g, 3 min). 150 µL of supernatant was removed from each sample and the 
remaining volume centrifuged (1136 x g, 3 min).  The pellets were washed with 200 µL 
of washing buffer (5M NaCl, 1M Tris/HCl pH8, 0.5 M EDTA pH8, ddH2O, 10% SDS), 
homogenised by vortexing and incubated for 20 min at 37 °C in a heating block. 
Afterwards the samples were centrifuged (1136 x g, 3 min) and supernatants removed. 
Negative control samples (no probes added) were screened by flow cytometry to detect 
background before the probe samples were re-suspended in an appropriate amount of 
PBS. Samples were stored at 4 °C until determinations. Numbers of specific and total 
bacteria were determined taking into account dilution factor (DF), calculate from 
different volumes used in samples preparation steps, and events/µl obtained from NON 
EUB338 and EUB338 I-II-III probes analysed by flow cytomotry. 
Metabolic analysis by 
1
H-NMR 
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Three consecutive days of the three biological replicates for each group (autistic and non-
autistic) of all time points (before and after treatment) were analysed by 
1
H-NMR (n=27, 
each group). Fermentation supernatants were defrosted, vortexed and centrifuged at 599 x 
g for 5 minutes. The supernatants were filtered using 0.22µm low protein binding 
Durapore polyvianylidene fluoride (PVDF) membranes (Millex; EMD Millipore, 
Billerica, MA, USA) and 400 μL transferred into fresh Eppendorf tubes. Filtered 
samples were combined with 200 μL of phosphate buffer (0.2 M (pH 7.4) in D2O plus 
0.001% TSP), mixed by vortexing, centrifuged at 1136 x g for 10 minutes and then 550 
μL was transferred into 5 mm NMR tubes for analysis. All NMR spectra were acquired 
on a Bruker Avance DRX 500 MHz NMR spectrometer (Bruker Biopsin, Rheinstetten, 
Germany) operating at 500 MHz. They were acquired using a standard one-dimensional 
(1D) pulse sequence [recycle delay (RD)-90°-t1-90°-tm-90°-acquire free induction decay 
(FID)] with water suppression applied during RD of 2 s, a mixing time Tm of 100 ms and 
a 90 pulse set at 7.70 μs. For each spectrum, a total of 128 scans were accumulated into 
64 k data points with a spectral width of 12.001 ppm. The FIDs were multiplied by an 
exponential function corresponding to 0.3 Hz line broadening.  
Data Preprocessing and Analysis 
All spectra were manually phased, baseline corrected and calibrated to the chemical shift 
of TSP (3-(trimethylsilyl)-[2,2,3,3,
-2
H4]-propionic acid, δ 0.00). Spectra were digitised 
using an in-house MATLAB (version R2014a, The Mathworks, Inc.; Natwick, MA) 
script. The spectral region containing the water resonance was removed to minimise 
distortions in the baseline arising from imperfect water saturation. Median fold 
normalization was performed for both groups, non-autistic and autistic children. Before 
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and after administration of B-GOS, principal components analysis (PCA) using mean-
centered data was applied. Orthogonal projection to latent structure discriminant analysis 
(OPLS-DA) models were constructed using unit variance scaling for pairwise 
comparisons of the different experimental groups and time points. Correlation 
coefficients plots were generated from the model outputs by back-scaling transformation 
to display the contribution of each variable (metabolites) to sample classification (e.g. 
before and after treatment). Colour represents the significance of correlation (R
2
) for each 
metabolite to class membership. Predictive strength (Q
2
Y) of the models was obtained 
using a seven-fold cross validation method and these were validated using permutation 
testing (number of permutations=10,000). 
Statistical analysis 
Data from HPLC and FMC-FISH analyses were analysed using paired T-test in order to 
assess significance of results, comparing the two time points SS1 and SS2, before and 
after treatment respectively. Statistical significance was at P<0.05 for all analyses. 
Analyses were performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, 
USA). 
 
Results 
Bacterial enumeration 
Changes in bacterial compositions in gut model systems are reported in Figure 1. The 
data showed lower numbers of bifidobacteria in ASD models compared to non-autistic 
ones. Significant increases in the Bifidobacterium spp, following addition of B-GOS to 
models containing both autistic and non-autistic samples were seen. In autistic models, a 
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significant increase of bifidobacteria occurred from 5.32 to 7.27 log10 cells/ml (P<0.01), 
from 4.81 to 6.79 log10 CFU/ml (P<0.001) and from 5.57 to 6.83 log log10 cells/ml 
(P<0.05), in V1, V2 and V3 respectively. A slight but significant increase in Clostridium 
cluster XI in V2 for autistic children was also found, as well as significant decrease in V2 
in Veillonellaceae group from 6.06 to 5 log10 CFU/ml (P<0.05). In non- autistic models, 
there was a significant increase in numbers of bifidobacteria in V1, from 5.83 to 7.16 log 
log10 cells/ml (P<0.01), and in V3, from 4.97 to 6.73 log10 cells/ml (P<0.001) and in 
lactic acid bacteria (Lab158) in V3 from 5.13 to 6.01 log10 cells/ml (P<0.05). 
Additionally, B-GOS slightly increased Roseburia spp. in V1 and 3 (P<0.05) and reduced 
Atopobium spp. from 6.06 to 5.28 log10 cells/ml and F. prausnitzii from 6.78 to 5.27 log10 
cells/ml (P<0.05 for both) in the second vessel, while increasing Atopobium spp. from 5 
to 5.92 log10 cells/ml (P<0.05) in the third vessel of non-autistic models. In these models, 
numbers of Clostridium coccoides - Eubacterium rectale were also increased from 6.76 
to 7.08 log10 cells/ml (P<0.01) in V1 and Sutterella spp. significantly decreased in V1 
from 7.05 to 6.49 (P<0.01) and V2 from 7.02 to 6.37 log10 CFU/ml (P<0.05) after B-GOS 
administration. There was a general trend to increase all other bacterial groups analysed 
in all vessels but this was not significant. Exceptions were seen for Bacteroides (V1), 
Clostridial Cluster IX (V1), F. prausnitzii (V1), E. coli (V3), Ruminococcus spp., 
Clostridium leptum (V2), Sutterella spp. and Veillonellaceae (all vessels) in autistic 
models, and for Clostridium coccoides - Eubacterium rectale (V2), Atopobium spp. (V1), 
Clostridial Cluster IX (V2), Clostridium cluster XI (V1, V2), E. coli (V2), Sutterella spp. 
and Veillonellaceae (all vessels) in non-autistic models that slightly decreased.  
Short chain fatty acids production 
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SCFAs concentrations are presented in Figure 2. Our data show a lower concentration of 
butyrate and propionate in autistic models, compared to non-autistic models, but no 
differences in acetate before adding B-GOS into the system. After administration of B-
GOS, acetate and butyrate were the main end products of microbial fermentation. 
Supplementation of B-GOS to gut models inoculated with faecal samples from autistic 
children, led to a significant increase of acetate and butyrate in V1 and 2, simulating the 
proximal and transverse colons (P<0.05) respectively, while concentration of propionate 
was decreased (P<0.05) in V3 mimicking distal colon. In models simulating the colon of 
non-autistic children, the fermentation of B-GOS mediated significant production of 
acetate (P<0.05) and butyrate (P<0.001) in V2 and 3, simulating the transverse and distal 
colon respectively. There was no effect on propionate.  
1
H-NMR Spectroscopic Profiles 
PCA analysis was performed on mean-centered data to summarise variance with the 
dataset. The scores plot (PC1 versus PC2) shown in Figure 3A, showed separation 
between autistic and non-autistic models after treatment, indicating that B-GOS 
supplementation contributed to the largest source of variance in the metabolic data. 
Comparison of the spectra profiles from gut models before and after treatment identified 
that a number of metabolites changed following B-GOS supplementation to characterise 
the metabolic variation associated with ASD, B-GOS supplementation and differences in 
microbial response to B-GOS between the ASD and non-ASD microbiota. The results of 
these analysis are summarised in Figure 3B. A significant OPLS-DA model was obtained 
comparing the metabolic profiles of the autistic and non-autistic models at baseline (Q
2
Y 
= 0.07; P < 0.05; Figure SC-I). Supernatants from the autistic models contained greater 
 by guest on N
ovem
ber 24, 2016
http://fem
sec.oxfordjournals.org/
D
ow
nloaded from
 
 13 
amounts of ethanol, glycine, tyrosine, tyramine, 5-aminopentoanate, acetate, 4-
aminobutyrate and betaine, compared to the non-autistic models and lower amounts of 
butyrate. B-GOS supplementation was found to modulate the metabolic profile of the 
autistic models (Q
2
Y = 0.08; P < 0.05) increasing ethanol, lactate, acetate and butyrate 
and decreasing propionate and trimethylamine (Figure SB-I). Increased butyrate and 
acetate production was also observed in the non-autistic models following the addition of 
BGOS (Q
2
Y = 0.12; P < 0.01; Figure SB-II). Comparing the metabolic profiles of the 
autistic and non-autistic models after B-GOS feeding (Q
2
Y = 0.17; P < 0.01) revealed 
that some of the metabolic variation was reduced (Figure SC-II). There was no longer 
variation in 4-aminobutyrate between the models, however the difference in ethanol and 
acetate between autistic and non-autistic models was increased being higher in the 
autistic models.  
Discussion 
Recent studies have focused on the effect of pre/probiotics on the gut-brain axis (Liu 
2015). This study investigated the influence of B-GOS on a small scale, in vitro, gut 
model system inoculated with faeces from autistic and non-autistic children. The results 
showed a positive modulation of bacterial populations, using an automated FISH method 
combined with flow cytometry. We also assessed metabolic profiles and key metabolites 
in both test groups.  
Lower concentrations of SCFAs have previously been found in ASD children by 
Adams et al. suggesting a reduced fermentation capacity by the ASD microbiota. It was 
hypothesised that this was due to a compromised microbiota characterised by a lower 
number of bifidobacteria, consistent with microbial signatures observed here (Adams 
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2011). Concomitant with these population changes, functional alterations were also 
observed in both autistic and non-autistic models with acetate and butyrate, the main end 
products of microbial fermentation, being increased.  
Recent studies have focused on SCFAs and their effect on the CNS. These 
fermentation products can cross the blood-brain barrier and might influence early brain 
development. The synthesis of neuroactive compounds such as dopamine and serotonin 
can be modulated by SCFA and they are able to produce reversible psychological and 
physiological changes in rats similar to those found in ASDs (Wang 2011). Experimental 
evidence using intraventricular infusion in rats indicates that propionic acid can produce 
brain and behavioural changes similar to ASD (MacFabe 2008).  
Recent ASD studies have shown increase in numbers of Sutterella spp. and 
decrease in Veillonellaceae group. In this study, the results did not show any significant 
differences between ASD and non-ASD group. However, a general decrease in those 
bacterial groups after treatment was highlighted, suggesting that B-GOS administration 
might have an impact on the growth of these ASD-associated bacteria.  
Following B-GOS feeding, the microbiota of autistic children produced greater 
amounts of ethanol and lactate while the amount of amino acids and the SCFA 
propionate, present in the model, was reduced. These metabolic alterations were not 
observed when the faecal microbiota of non-autistic individual were fed B-GOS. In a 
healthy colon, lactate production is generally low due to its conversion to other organic 
acids by many bacteria and because lactate can be used as a substrate for dissimilation of 
sulphate by some bacteria (e.g. Desulfovibrio spp.) (Flint 2014;  Marquet 2009;  Fite 
2004). In ASD children presence of lactate is interesting because its accumulation has 
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been associated to neurological problems, in particular studies show the effect of lactate 
infusions on anxiety and panic disorders (Dillon 1987;  Cowley 1987). Cowley and 
colleagues in their findings showed that lactate infusion in patients suffering from panic 
disorder, provoke higher panic symptoms reaction compared to controls (Dillon 1987). 
Dillon et al. have showed similar results in in vivo, where panic and anxiety reaction has 
been measured using Acute Panic Inventory (API) scores. After lactate infusions the 
scores were much higher in patients with panic and anxiety disorders compared to normal 
controls (Cowley 1987). 
The lysine degradation product, 5-aminopentanoic acid, was also higher in the 
autistic compared to the non-autistic models. This metabolite can be produced both 
endogenously or through the bacterial catabolism of lysine. It is believed to act as a 
methylene homologue of γ-aminobutyric acid (GABA) and functions as a weak GABA 
agonist (Callery 1985). Interestingly, GABA was also higher in the autistic models 
compared to the non-autistic models pre-treatment but these differences were not present 
following B-GOS treatment. Certain bacteria, such as lactobacilli, are able to produce 
molecules that acts as neurotransmitters and directly affect the brain (Wall 2014). In our 
results, its reduction might be due to changes in gut microbiota composition.  
Ethanol was found in higher amount in ASD children comparing to non-ASD. 
The vast majority of bacteria form ethanol from acetyl-CoA and the glycolytic pathway 
(Macfarlane 2003). Microorganisms are able to oxidase ethanol and the impact of 
bacterial overgrowth on ethanol production has previously been studied (Baraona 1986). 
Metabolism of ethanol can lead to the production of toxic end-products such as 
acetaldehyde, which may affect the gastrointestinal mucosa. The role of acetaldehyde in 
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ASD has been recently evaluated in particular for its role in oxidative stress and DNA 
damage. Under healthy conditions, ethanol is converted into acetic acid in the liver by a 
two-step process involving alcohol dehydrogenase (ADH) and aldehyde dehydrogenase 
(ALDH). Mutation of the ALDH gene has been shown to increase the accumulation of 
acetaldehyde and result in cancers within different regions of the gastrointestinal tract and 
Alzheimer’s disease (Jurnak 2015). The potential role of this toxic compound in 
neurological disorders, including autism, warrants further exploration.  
Conclusions 
This in vitro study showed promising and positive results in that supplementing 
the microbiota of ASD children with 65%B-GOS may manipulate the gut bacterial 
population and alter metabolic activity towards a configuration that might represent a 
health benefit to the host. However, further work will be required to assess such changes 
in an in vivo human intervention study. 
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Table 1. Oligonucleotide probes used in this study for FISH-FCM analysis of bacterial populations. +: 
These probes are used together in equimolar concetration of 50 ng/μl. 
PROBE 
NAME 
SEQUENCE (5’ TO 3’) TARGET GROUP REFERENCE 
Non Eub ACTCCTACGGGAGGCAGC  Wallner 1993 
Eub338 I + GCT GCC TCC CGT AGG AGT Most Bacteria Daims 1999 
Eub338 II + GCA GCC ACC CGT AGG TGT Planctomycetales Daims 1999 
Eub338 III + GCT GCC ACC CGT AGG TGT Verrucomicrobiales Daims 1999 
Bif164 CAT CCG GCA TTA CCA CCC Most Bifidobacterium spp. and 
Parascardovia denticolens 
Langendijk 
1995 
Lab158 GGTATTAGCAYCTGTTTCCA Most Lactobacillus, Leuconostoc and 
Weissella spp.; Lactococcus lactis; all 
Vagococcus, Enterococcus, Melisococcus, 
Tetragenococcus, Catellicoccus, 
Pediococcus and Paralactobacillus spp 
Harmsen 1999 
Bac303 CCA ATG TGG GGG ACC TT Most Bacteroidaceae and Prevotellaceae, 
some Porphyromonadaceae 
Manz 1996 
Clit135 GTTATCCGTGTGTACAGGG  Some of the Clostridium lituseburense 
group (Clostridium cluster XI) 
Manz 1996 
Erec482 GCT TCT TAG TCA RGT ACCG Most of the Clostridium coccoides-
Eubacterium rectale group 
(Clostridium cluster XIVa and XIVb) 
Manz 1996 
Chis150 TTATGCGGTATTAATCTYCCTTT Most of the Clostridium histolyticum group 
(Clostridium cluster I and II) 
Franks 1998 
Rrec584 TCA GAC TTG CCG YAC CGC Roseburia sub cluster Franks 1998 
Prop853 ATT GCG TTA ACT CCG GCAC Clostridial Cluster IX Walker 2005 
Ato291 GGT CGG TCT CTC AAC CC Atopobium, Colinsella, Olsenella and 
Eggerthella spp.; Cryptobacterium curtum; 
Mycoplasma equigenitalium and 
Mycoplasma elephantis 
Harmsen 2000 
Fprau655 CGCCTACCTCTGCACTAC Faecalibacterium prausnitzii and related 
sequences 
Hold 2003 
DSV687 TAC GGA TTT CAC TCC T Most Desulfovibrionales (excluding 
Lawsonia) and many Desulfuromonales 
Devereux 1992 
EC1531 CACCGTAGTGCCTCGTCATCA  Escherichia coli BJ4 Poulsen 1995 
Rbro730 + TAAAGCCCAGYAGGCCGC  Clostridium sporosphaeroides, 
Ruminococcus bromii, Clostridium leptum 
Harmsen 2002;  
Lay 2005 
Rfla729 + AAA GCC CAG TAA GCC GCC Ruminococcus albus, R. flavefaciens Harmsen 2002;  
Lay 2005 
SUBU1237 CCC TCT GTT CCG ACC ATT Burkholderia spp., Sutterella spp. Stoffels 1998 
Vei723 ACA CAG TCC AGA AAG GCG Veillonellaceae Kong 2012 
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Figure 1. Bacterial groups detected by FISH-FCM (Log10 CFU/ml ± SD) in culture 
broth recovered from each vessel (V1, V2 and V3) of a colonic model before (SS1) and 
after (SS2) the daily administration of B-GOS (2g/d, equivalent to 1g GOS). Significant 
difference after the treatment: * P<0.05; **P<0.01; ***P<0.001. Probes: Total bacteria 
(Eub338I-II-III), Bifidobacterium spp. (Bif164), Lactobacillus spp. (Lab158), Most 
Bacteroidaceae and Prevotellaceae (Bac303), Clostridium coccoides-Eubacterium rectale 
group (Erec482), Roseburia sub cluster (Rrec584), F. prausnitzii (Fprau655), Clostridium 
cluster XI (Clit135), Sutterella spp. (SUBU1237), Veillonellaceae (VEI732), Atopobium 
spp. (Ato291). (A) autistic children; (B) non-autistic children. 
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Figure 2. HPLC analysis. Acetate, propionate and butyrate concentrations in culture 
broths recovered from vessels (V1, V2 and V3) of in vitro gut model systems before 
(SS1) and after (SS2) administration of B-GOS (1g/daily GOS). Results are reported as 
means (mM) of the data (n=3): A) autistic children and B) non-autistic children. 
Significant difference after the treatment: * P<0.05; ***P<0.001. 
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Figure 3. 
1
H-NMR data analysis. (A) PCA score plot show a separation between 
models inoculated with stool samples of non-ASD and ASD children after administration 
of B-GOS. Dark and light blue dots represent replicates of samples from gut models 
inoculated with faecal samples of autistic children, before (SS1) and after (SS2) treatment 
respectively. Yellow and red dots represent replicates of samples from gut models 
inoculated with faecal samples of non-autistic children, before (SS1) and after (SS2) 
treatment respectively. (B) Correlation coefficients indicating the associations of 
identified metabolites with autism and their alteration upon B-GOS administration. SS1: 
before treatment; SS2: after treatment. White cells represent no significant correlations.  
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